SCHAUMBURG, Ill., March 25 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched Cefepime for injection, USP, a broad ...

Compared with meropenem, cefepime-taniborbactam is superior for microbiologic and clinical cure of complicated urinary tract infection, including acute pyelonephritis. Cefepime-taniborbactam is more ...

Topline Data from Phase 3 clinical trial of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs) expected first quarter 2022 BARDA extends cost-sharing contract to ...

The phase 3 CERTAIN-1 study compared the efficacy and safety of cefepime-taniborbactam to meropenem in 661 adults with cUTI. Positive results were announced from a phase 3 study evaluating ...

Credit: Getty Images. A PDUFA target date of February 22, 2024 has been set for this application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...

IV- UTI- The recommended dose is 0.5-1 g 12 hourly for 7-10 days. Empirical therapy for febrile neutropenia- 2 g 8 hourly for 7 days or until resolution of neutropenia. It comes as a solution for ...

The frequency of neutropenia in patients receiving long-term cefepime therapy for osteomyelitis compared with that in patients receiving other antimicrobials was studied. A comparative case review was ...

November 4, 2009 (Philadelphia, Pennsylvania) — Despite concerns raised after a meta-analysis suggested that increased mortality is associated with cefepime use in patients with febrile neutropenia ...

IV- UTI- The recommended dose is 0.5-1 g 12 hourly for 7-10 days. Empirical therapy for febrile neutropenia- 2 g 8 hourly for 7 days or until resolution of neutropenia. It comes as a solution for ...